Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Ophthalmological Medicine
Volume 2016, Article ID 2798304, 3 pages
http://dx.doi.org/10.1155/2016/2798304
Case Report

Bilateral Lacrimal Gland Lymphoma in Sjögren Syndrome

1Department of Ophthalmology, Faculty of Medicine, Ege University, Izmir, Turkey
2Department of Pathology, Faculty of Medicine, Ege University, Izmir, Turkey
3Department of Hematology, Faculty of Medicine, Ege University, Izmir, Turkey

Received 14 July 2016; Accepted 28 August 2016

Academic Editor: Alexander A. Bialasiewicz

Copyright © 2016 Melis Palamar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. I. Fox, F. V. Howell, R. C. Bone, and P. E. Michelson, “Primary sjogren syndrome: clinical and immunopathologic features,” Seminars in Arthritis and Rheumatism, vol. 14, no. 2, pp. 77–105, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. N. A. Cummings, G. L. Schall, R. Asofsky et al., “Sjögren's syndrome: newer aspects of research diagnosis and therapy,” Annals of Internal Medicine, vol. 75, pp. 937–950, 1971. View at Google Scholar
  3. H. Tonami, M. Matoba, Y. Kuginuki et al., “Clinical and imaging findings of lymphoma in patients with Sjögren syndrome,” Journal of Computer Assisted Tomography, vol. 27, no. 4, pp. 517–524, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Theander, G. Henriksson, O. Ljungberg, T. Mandl, R. Manthorpe, and L. T. H. Jacobsson, “Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors,” Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 796–803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Solans-Laqué, A. López-Hernandez, J. Angel Bosch-Gil, A. Palacios, M. Campillo, and M. Vilardell-Tarres, “Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome,” Seminars in Arthritis and Rheumatism, vol. 41, no. 3, pp. 415–423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Sutcliffe, M. Inanc, P. Speight, and D. Isenberg, “Predictors of lymphoma development in primary Sjögren's syndrome,” Seminars in Arthritis and Rheumatism, vol. 28, no. 2, pp. 80–87, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Voulgarelis, U. G. Dafni, D. A. Isenberg, and H. M. Moutsopoulos, “Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1765–1772, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. J. S. Goda, M. Gospodarowicz, M. Pintilie et al., “Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy,” Cancer, vol. 116, no. 16, pp. 3815–3824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Kahl and D. Yang, “Marginal zone lymphomas: management of nodal, splenic, and MALT NHL,” Hematology/The Education Program of the American Society of Hematology, vol. 2008, no. 1, pp. 359–364, 2008. View at Publisher · View at Google Scholar